BioLife Solutions, Inc. affirming revenue guidance for the year 2022. Total revenue for 2022 is expected to range from $159.5 million to $171.0 million, reflecting year-over-year growth of 34% to 44% and organic growth of 28% to 39%. COVID-19 related revenue is expected to account for approximately 8% to 9% of total revenue.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21 USD | -4.04% | -3.71% | +30.18% |
13/05 | Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target | MT |
09/05 | Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.18% | 100.72Cr | |
-5.33% | 18TCr | |
-0.36% | 11TCr | |
-5.70% | 6.78TCr | |
+1.71% | 5.19TCr | |
+7.50% | 4.32TCr | |
+6.07% | 4.11TCr | |
+22.45% | 3.21TCr | |
+15.86% | 2.5TCr | |
-4.12% | 2.45TCr |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- Biolife Solutions, Inc. Affirms Revenue Guidance for the Year 2022